muscle disorder drug

Here’s Why Novartis Is Paying $500M to Acquire a Preclinical RNA Startup

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.